A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
作者： A. Clamp , M. Adams , R. Atkinson , E. Boven , A.H. Calvert
DOI: 10.1016/J.YGYNO.2004.06.047
关键词:
摘要: … of exatecan at these schedules in ovarian cancer, preclinical data suggest that exploration of different schedules of administration or exatecan-… of tumour cells to exatecan may increase …
openrepository.com
gynecologiconcology-online.net
manchester.ac.uk
elsevier.com参考文章(30)
E. N. Anderson, Hudson et al. Journal of California Anthropology, The. ,vol. 4, ,(1977)
, , International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute. ,vol. 95, pp. 105- 112 ,(2003) , 10.1093/JNCI/95.2.105
Y H Hsiang, R Hertzberg, S Hecht, L F Liu, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry. ,vol. 260, pp. 14873- 14878 ,(1985) , 10.1016/S0021-9258(17)38654-4
Martin Gore, Wim ten Bokkel Huinink, James Carmichael, Alan Gordon, Neville Davidson, Robert Coleman, Marek Spaczynski, Jean-François Héron, Giorgio Bolis, Henric Malmström, John Malfetano, Claudio Scarabelli, Phillipe Vennin, Graham Ross, Scott Z. Fields, Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer Journal of Clinical Oncology. ,vol. 19, pp. 1893- 1900 ,(2001) , 10.1200/JCO.2001.19.7.1893
G J Creemers, G Bolis, M Gore, G Scarfone, A J Lacave, J P Guastalla, R Despax, G Favalli, R Kreinberg, S Van Belle, I Hudson, J Verweij, W W Ten Bokkel Huinink, Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of Clinical Oncology. ,vol. 14, pp. 3056- 3061 ,(1996) , 10.1200/JCO.1996.14.12.3056
Hironobu Minami, Yasutsuna Sasaki, Kuniaki Itoh, Kyoji Tamanoi, Hirofumi Fujii, Toshihiro Oguma, Tadahiko Igarashi, Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clinical Cancer Research. ,vol. 7, pp. 3056- 3064 ,(2001)
W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, I Hudson, C Broom, C Scarabelli, N Davidson, M Spanczynski, G Bolis, H Malmström, R Coleman, S C Fields, J F Heron, Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 15, pp. 2183- 2193 ,(1997) , 10.1200/JCO.1997.15.6.2183
Nancy Kemeny, David Ilson, David Kelsen, Ellen Hollywood, Gary K. Schwartz, John Coyle, Eileen O’Reilly, Leonard B. Saltz, Sunil Sharma, Sarah Kleban, Robert L. De Jager, Martin P. Ducharme, Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical Cancer Research. ,vol. 7, pp. 3963- 3970 ,(2001)
G J Rustin, A E Nelstrop, P McClean, M F Brady, W P McGuire, W J Hoskins, H Mitchell, H E Lambert, Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. Journal of Clinical Oncology. ,vol. 14, pp. 1545- 1551 ,(1996) , 10.1200/JCO.1996.14.5.1545
E K Rowinsky, L B Grochow, C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology. ,vol. 10, pp. 647- 656 ,(1992) , 10.1200/JCO.1992.10.4.647